Anika Therapeutics (ANIK) Non-Current Assets (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Non-Current Assets data on file, last reported at $85.8 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $85.8 million, down 2.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $349.0 million (down 8.2% YoY), and the FY2025 annual result was $86.9 million, down 2.44% from the prior year.
• Non-Current Assets declined to $85.8 million in Q1 2026 per ANIK's latest filing, from $86.9 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $186.3 million in Q2 2022 and troughed at $85.8 million in Q1 2026.
• A 5-year average of $128.9 million and a median of $107.3 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets grew 1.03% in 2023, then slumped 44.39% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $179.6 million in 2022, then tumbled by 40.24% to $107.3 million in 2023, then decreased by 16.99% to $89.1 million in 2024, then retreated by 2.44% to $86.9 million in 2025, then dropped by 1.25% to $85.8 million in 2026.
• Business Quant data shows ANIK's Non-Current Assets at $85.8 million in Q1 2026, $86.9 million in Q4 2025, and $87.8 million in Q3 2025.